The company that devotes to the development of active natural, Vytrus Biotech, published the last week the results of his financial activity between the months of January and June of this 2022.
In the inform, the company indicated that their turnover had surpassed the 2 million euros, what wants to say that it achieved a growth of 51% with regard to June of 2021. Regarding the sale of theiir products, did it in 33 countries increasing the volume in United States, Europe and Latam.
Regarding figure of profits, Vytrus obtains an EBITDA of 0.86 million euros, 62% more comparing the profits with the profits obtained last year. The company also wants to stand out the growth in the evolution of the Cash Flow Gross (sum of the net profit after taxes/resulted of the exercise and amortizaciones and provisions), that exceed the 500 one thousand euros and increases 152% with regard to June of 2021.
Vytrus Stood out that the investment in R&D surpassed the 360 one thousand euros, 8% more than in the same period of the previous year, and indicate that in the second semester of this year will achieve to grow 7% to attain 15%. Regarding the investment in CAPEX (fixed capital), Vytrus has allocated more than 290.000 euros in the enlargement of his laboratories and purchase new teams in his area of production, laboratory and offices.
The company with headquarters in Terrassa, presents some healthy accounts with a cash flow of more than EUR 1 million, and a financial debt of 1,9 million euros. With regard to the financial costs, reached 122 one thousand euros and the company has improved their financial ratios: it increases the one of his own bottoms in 9% (4.63 million euros, with regard to the 4.25 millions in June of 2021), and, as far as the working capital is concerned, the figure amounts to more than EUR 1 million.
The purposes of the mark continue intact: innovation and sustainability, thus, Jordi Rovira, of Vytrus has stood out that exists a greater dedication of resources in these areas: "Vytrus follows presenting a balance very healthy and balanced. It interests us grow in sales and in quota of market, but still interests us grow more in profitability. We understand that they come time that this goes to be a maximum for the investor to the that every time goes him to cost more fund projects that do not generate box in a reasonable term of time."